C5a/C5aR interaction mediates complement activation and thrombosis on endothelial cells in atypical hemolytic uremic syndrome (aHUS)

Sara Gastoldi; Marina Noris; Paolo Macor; Francesco Tedesco; Federica Banterla; Elena Bresin; Roberta Donadelli; Giuseppe Remuzzi; Miriam Galbusera

doi:10.1016/j.imbio.2012.08.049

Related publications

Letter2019

Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?

Marina Noris, Giuseppe Remuzzi

Article2025

Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays

Donata Santarsiero, Sara Gastoldi, Valeria Guaschino, Elena Bresin, I Pagani, Andrea Pasini, Elena Romano, Ariela Benigni, Giuseppe Remuzzi, Marina Noris, Sistiana Aiello

Article2013

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus, Larry A. Greenbaum, Sunil Babu, Camille L. Bedrosian, Coralie Bingham, D.J. Cohen, Yahsou Delmas, K. Douglas, Frank Eitner, Thorsten Feldkamp, Denis Fouque, Richard R. Furman, Osama Gaber, Maria Herthelius, Maryvonne Hourmant, Diana Karpman, Yvon Lebranchu, Christophe Mariat, Jan Menne, Bruno Moulin, Jens Nürnberger, Masayo Ogawa, Giuseppe Remuzzi,

Article2011

In patients with atypical hemolytic uremic syndrome C5 activation causes loss of endothelial thromboresistance

Miriam Galbusera, Silvia Gastoldi, Federica Banterla, Paolo Macor, Elena Bresin, Roberta Donadelli, Francesco Tedesco, Giuseppe Remuzzi, Marina Noris

Article2013

Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype

Elena Bresin, Erica Rurali, Jessica Caprioli, Pilar Sánchez‐Corral, Véronique Frémeaux‐Bacchi, Santiago Rodrı́guez de Córdoba, Sheila Pinto, Timothy H.J. Goodship, Marta Alberti, David Ribes, Elisabetta Valoti, Giuseppe Remuzzi, Marina Noris